UY39681A - Derivados de ciclobutilo 1,3–sustituidos y sus usos - Google Patents
Derivados de ciclobutilo 1,3–sustituidos y sus usosInfo
- Publication number
- UY39681A UY39681A UY0001039681A UY39681A UY39681A UY 39681 A UY39681 A UY 39681A UY 0001039681 A UY0001039681 A UY 0001039681A UY 39681 A UY39681 A UY 39681A UY 39681 A UY39681 A UY 39681A
- Authority
- UY
- Uruguay
- Prior art keywords
- substituted cyclobutyl
- treatment
- disorders
- diseases
- derivatives
- Prior art date
Links
- 125000001995 cyclobutyl group Chemical class [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 title 1
- 208000022873 Ocular disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108010025083 TRPV1 receptor Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En el presente documento se proporcionan compuestos y composiciones farmacéuticas útiles para el tratamiento de enfermedades o trastornos mediados por el receptor TRPV1. La presente invención además proporciona métodos para el tratamiento de enfermedades o trastornos oculares mediante la administración, a un sujeto que lo necesita, de una cantidad terapéuticamente eficaz de un compuesto de Fórmula (I) o una composición farmacéutica descriptos en el presente documento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166289P | 2021-03-26 | 2021-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39681A true UY39681A (es) | 2022-10-31 |
Family
ID=80999265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039681A UY39681A (es) | 2021-03-26 | 2022-03-22 | Derivados de ciclobutilo 1,3–sustituidos y sus usos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11845730B2 (es) |
| EP (1) | EP4313951A1 (es) |
| JP (1) | JP2024510778A (es) |
| KR (1) | KR20230162660A (es) |
| CN (1) | CN117062804A (es) |
| AR (1) | AR125196A1 (es) |
| AU (1) | AU2022244467A1 (es) |
| BR (1) | BR112023019496A2 (es) |
| CA (1) | CA3214066A1 (es) |
| IL (1) | IL307189A (es) |
| TW (1) | TW202304864A (es) |
| UY (1) | UY39681A (es) |
| WO (1) | WO2022201097A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024062389A1 (en) * | 2022-09-21 | 2024-03-28 | Bausch + Lomb Ireland Limited | Crystalline polymorph forms of a trpv1 antagonist and formulations thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| WO2008007780A1 (fr) * | 2006-07-13 | 2008-01-17 | Kyowa Hakko Kirin Co., Ltd. | Dérivé du pentadiènamide |
| JP5405314B2 (ja) | 2006-12-27 | 2014-02-05 | サノフイ | シクロアルキルアミン置換イソキノロン誘導体 |
| DE102010052781A1 (de) * | 2010-11-30 | 2012-05-31 | Trw Automotive Gmbh | Befestigungsvorrichtung und Befestigungsbaugruppe zur Befestigung eines Gasgenerators und Fahrzeuginsassenrückhaltesystem |
| JP5934778B2 (ja) | 2011-03-25 | 2016-06-15 | アッヴィ・インコーポレイテッド | Ｔｒｐｖ１拮抗薬 |
| EP2697221A1 (en) * | 2011-04-11 | 2014-02-19 | Glaxo Group Limited | N- cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists |
| WO2017079162A1 (en) | 2015-11-02 | 2017-05-11 | Castar, Inc | Method of immersive rendering for wide field of view |
| US10269906B2 (en) * | 2016-11-30 | 2019-04-23 | Taiwan Semiconductor Manufacturing Co., Ltd. | Semiconductor device having two spacers |
| WO2018151678A1 (en) * | 2017-02-15 | 2018-08-23 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| NZ777458A (en) | 2018-12-07 | 2024-03-22 | Univ Maryland | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
-
2022
- 2022-03-22 UY UY0001039681A patent/UY39681A/es unknown
- 2022-03-22 AR ARP220100676A patent/AR125196A1/es unknown
- 2022-03-24 BR BR112023019496A patent/BR112023019496A2/pt unknown
- 2022-03-24 CA CA3214066A patent/CA3214066A1/en active Pending
- 2022-03-24 IL IL307189A patent/IL307189A/en unknown
- 2022-03-24 AU AU2022244467A patent/AU2022244467A1/en active Pending
- 2022-03-24 JP JP2023558324A patent/JP2024510778A/ja active Pending
- 2022-03-24 EP EP22714016.7A patent/EP4313951A1/en active Pending
- 2022-03-24 CN CN202280024266.2A patent/CN117062804A/zh active Pending
- 2022-03-24 US US17/656,313 patent/US11845730B2/en active Active
- 2022-03-24 WO PCT/IB2022/052720 patent/WO2022201097A1/en active Application Filing
- 2022-03-24 TW TW111111060A patent/TW202304864A/zh unknown
- 2022-03-24 KR KR1020237036535A patent/KR20230162660A/ko unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230162660A (ko) | 2023-11-28 |
| BR112023019496A2 (pt) | 2023-12-05 |
| AU2022244467A1 (en) | 2023-10-12 |
| US11845730B2 (en) | 2023-12-19 |
| AR125196A1 (es) | 2023-06-21 |
| TW202304864A (zh) | 2023-02-01 |
| EP4313951A1 (en) | 2024-02-07 |
| WO2022201097A1 (en) | 2022-09-29 |
| CA3214066A1 (en) | 2022-09-29 |
| CN117062804A (zh) | 2023-11-14 |
| IL307189A (en) | 2023-11-01 |
| US20220324811A1 (en) | 2022-10-13 |
| JP2024510778A (ja) | 2024-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21004787A (es) | Inhibidores de inflamasoma nlrp3 | |
| ATE440834T1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| DOP2010000064A (es) | 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| ATE453636T1 (de) | Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren | |
| MX2023007140A (es) | Compuestos farmaceuticos. | |
| UY38625A (es) | Compuestos y su uso en el tratamiento del cáncer | |
| CO2022000749A2 (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| ECSP22040362A (es) | Derivados de 1,2,4oxadiazol como agonistas del receptor hepático x | |
| UY39681A (es) | Derivados de ciclobutilo 1,3–sustituidos y sus usos | |
| AR127470A1 (es) | Inhibidores de lrrk2 | |
| ECSP19084722A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
| EA202190339A1 (ru) | Пиридопиримидины в качестве ингибиторов н4-гистаминовых рецепторов | |
| CL2021000282A1 (es) | Inhibidores de ckd8/19 | |
| AR069569A1 (es) | Derivados de benzoxazina, un intermediario para su preparacion, una composicion farmaceutica que los comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de renina. | |
| ZA202306305B (en) | Pharmaceutical compounds | |
| AR123685A1 (es) | Antagonistas del mrgx2 | |
| TW202416955A (zh) | 毒蕈鹼受體激動劑 | |
| WO2024028458A3 (en) | Crystalline forms and salts of a muscarinic receptor agonist | |
| PE20240358A1 (es) | Derivados de tetrahidrotieno piridina como inhibidores de ddr | |
| AR127170A1 (es) | Antagonistas del receptor de la hormona paratiroidea (pth) y sus usos | |
| EA202091047A1 (ru) | Пиридинкарбонильные производные и их терапевтические применения в качестве ингибиторов trpc6 |